{"nctId":"NCT00370071","briefTitle":"Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250Âµg in Patients of Chinese Origin With Multiple Sclerosis","startDateStruct":{"date":"2006-11"},"conditions":["Multiple Sclerosis"],"count":39,"armGroups":[{"label":"Interferon beta-1b (Betaseron, BAY86-5046)","type":"EXPERIMENTAL","interventionNames":["Drug: Interferon beta-1b (Betaseron, BAY86-5046)"]}],"interventions":[{"name":"Interferon beta-1b (Betaseron, BAY86-5046)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Chinese origin\n* diagnosis of Relapsing remitting multiple sclerosis or secondary progressive multiple sclerosis\n\nExclusion Criteria:\n\n* Any disease other than Multiple Sclerosis (MS) that could better explain the patients signs and symptoms\n* HIV (human immunodeficiency virus) infections\n* Hepatitis A\n* Syphilis\n* immunodeficiency\n* rheumatic disease or Sjogren syndrome\n* heart disease\n* severe depression\n* pregnancy or lactation\n* conditions interfering with Magnetic Resonance Imaging (MRI)\n* Gadolinium DTPA (Gadovist, contrast agent) allergy\n* allergy against human proteins, paracetamol, acetaminophen and ibuprofen intolerance\n* participation in other trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"55 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Difference Between the Number of Newly Active Lesions in Magnetic Resonance Imaging (MRI) Per Three Months During the 6-month Treatment Period and the Number of Newly Active Lesions During 3-month Pre-treatment","description":"The primary efficacy variable was calculated by subtracting the number of newly active lesions during the 3-month pre-treatment period from the cumulative number of newly active lesions during the 6-month treatment period divided by 2 (number of newly active lesions per three months, new lesion frequency per 3 months)","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Difference Between the Number of New Gadolinium (Gd)-Enhancing Lesions Per 3 Months During the 6-month Treatment Period and the Number of New Gd-enhancing Lesions During 3-month Pre-treatment","description":"This secondary endpoint (component of the primary endpoint) was calculated by subtracting the number of new Gd-enhancing lesions during the 3-month pre-treatment period from the cumulative number of new Gd-enhancing lesions during the 6-month treatment period divided by 2 (number of new Gd-enhancing lesions per three months)","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Difference Between the Number of New or Enlarging T2 Lesions Per 3 Months During the 6-month Treatment Period and the Number of New or Enlarging T2 Lesions During 3-month Pre-treatment","description":"This secondary endpoint (component of the primary endpoint) was calculated by subtracting the number of new or enlarging T2 lesions during the 3-month pre-treatment period from the cumulative number of new or enlarging T2 lesions during the 6-month treatment period divided by 2 (number of new T2 lesions per three months) based on non-enhancing lesions on T1 weighted scans","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Volume of Gadolinium-enhancing Lesions at Baseline, Weeks 12 and 24","description":"In the categories listed below, \"N\" signifies the number of subjects evaluable for the timepoints.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"585","spread":"869"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":"184"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"648","spread":"2788"}]}]}]},{"type":"SECONDARY","title":"Number of New Gadolinium (T1)-Enhancing Lesions at Baseline, Weeks 12 and 24","description":"In the categories listed below, \"N\" signifies the number of subjects evaluable for the timepoints.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"4.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"1.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"1.83"}]}]}]},{"type":"SECONDARY","title":"Number of T2 Lesions at Baseline, Weeks 12 and 24","description":"In the categories listed below, \"N\" signifies the number of subjects evaluable for the timepoints.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.7","spread":"35.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.8","spread":"35.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.6","spread":"31.54"}]}]}]},{"type":"SECONDARY","title":"Assessment of Relapses: Relapse Rate","description":"A relapse was defined as the appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical event. The abnormality must be present for at least 24 hours and occur in the absence of fever (axillary temperature more than (\\>) 37.5 degree celsius / 99.5 degree fahrenheit) or known infection. A relapse must be confirmed by a documented report from a physician or by objective assessment. The relapse rate was calculated on an annualized basis. Annualized relapse rate is the average number of relapses in a year calculated by negative binomial regression as the sum of confirmed relapses of all subjects in the group divided by the sum of the number of days on study of all subjects in the group and multiplied by 365.25.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.38","spread":null}]}]}]},{"type":"SECONDARY","title":"Assessment of Relapses: Number of Relapses","description":"A relapse was defined as the appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical event. The abnormality must be present for at least 24 hours and occur in the absence of fever (axillary temperature \\>37.5 degree celsius / 99.5 degree fahrenheit) or known infection. A relapse must be confirmed by a documented report from a physician or by objective assessment. In the categories listed below, \"N\" signifies the number of subjects evaluable for the timepoints, and same subjects were counted more than once under each category.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Assessment of Relapses: Percentage of Relapse-free Subjects After 24 Weeks","description":"A relapse was defined as the appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical event. The abnormality must be present for at least 24 hours and occur in the absence of fever (axillary temperature \\>37.5 degree celsius / 99.5 degree fahrenheit) or known infection. A relapse must be confirmed by a documented report from a physician or by objective assessment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Assessment of Relapses: Relapse Severity","description":"A relapse was defined as the appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical event. The abnormality must be present for at least 24 hours and occur in the absence of fever (axillary temperature \\>37.5 degree celsius / 99.5 degree fahrenheit) or known infection. A relapse must be confirmed by a documented report from a physician or by objective assessment. A major relapse was defined based on changes on EDSS with the following additional criteria to be met: objective neurological impairment, correlating with the subject's reported symptoms, defined as either increase in at least one of the functional systems of the EDSS score or increase of the total EDSS score. Relapses which did not meet the criteria of major relapses were considered as non-major.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Expanded Disability Status Scale (EDSS)","description":"The EDSS is a scale based on the standardized neurological examination which comprised of optic, brain stem/cranial nerves, pyramidal, cerebellar, sensory, vegetative, and cerebral functions, as well as walking ability. The EDSS scores range from 0.0 (normal) to 10.0 (dead). A score of 2 to 3 indicates minimal to moderate disability.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.06","spread":"1.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.81","spread":"1.72"}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Without EDSS Progression","description":"The EDSS is a scale based on the standardized neurological examination which comprised of optic, brain stem/cranial nerves, pyramidal, cerebellar, sensory, vegetative, and cerebral functions, as well as walking ability.The EDSS scores range from 0.0 (normal) to 10.0 (dead). A score of 2 to 3 indicates minimal to moderate disability. An EDSS progression was defined as increase in EDSS greater than or equal to (\\>=) 1.0 points (in the treatment period as compared to baseline).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":39},"commonTop":["Influenza like illness","Hepathic function abnormal","Headache","Myalgia","Injection site pain"]}}}